Table 2.
Univariate logistic regression results for associations with treatment interruptions
| Characteristics | Odds ratio | Lower 95%CI | Upper 95%CI | p | |
|---|---|---|---|---|---|
| Country of origin | Middle East | Reference | |||
| Asia | 1.33 | 0.43 | 4.08 | 0.62 | |
| Africa | 1.27 | 0.53 | 3.05 | 0.60 | |
| Europe/USA | 0.30 | 0.09 | 1.04 | 0.06 | |
| Age at diagnosis (years) | ≤Mean | Reference | |||
| >Mean | 0.92 | 0.51 | 1.64 | 0.77 | |
| Body mass index | <25 | Reference | |||
| 25–29 | 1.29 | 0.55 | 3.03 | 0.57 | |
| ≥30 | 1.51 | 0.70 | 3.25 | 0.29 | |
| Menopausal status | Premenopausal | Reference | |||
| Postmenopausal | 1.19 | 0.67 | 2.12 | 0.56 | |
| Marital status | Married | Reference | |||
| Single | 0.25 | 0.03 | 1.93 | 0.18 | |
| Financial status | Medical insurance | Reference | |||
| Cash payer | 0.77 | 0.43 | 1.36 | 0.36 | |
| Commuting distance to treatment facility (km) | ≤50 | Reference | |||
| 51–100 | 1.04 | 0.46 | 2.36 | 0.93 | |
| >100 | 1.46 | 0.54 | 3.99 | 0.46 | |
| Planning target volume (PTV) | Chest wall | Reference | |||
| Whole breast | 0.74 | 0.42 | 1.33 | 0.31 | |
| Volume of PTV (cm3) | ≤652 | Reference | |||
| 653–872 | 0.47 | 0.19 | 1.14 | 0.09 | |
| 873–1235 | 0.50 | 0.20 | 1.22 | 0.13 | |
| ≥1236 | 0.51 | 0.21 | 1.24 | 0.14 | |
| Locoregional lymph nodes treated as part of plan | Yes | Reference | |||
| No | 0.64 | 0.36 | 1.14 | 0.13 | |
| Boost to the tumor bed | Yes | Reference | |||
| No | 1.85 | 1.03 | 3.31 | 0.04 | |
| Radiotherapy technique | IMRT | Reference | |||
| 3DCRT | 0.93 | 0.52 | 1.66 | 0.80 | |
| Fractionation regimen | CF | Reference | |||
| HF | 2.32 | 1.27 | 4.26 | <0.01 | |
| Number of radiotherapy fractions | ≤15 | Reference | |||
| 16–20 | 0.68 | 0.25 | 1.83 | 0.44 | |
| 21–28 | 0.79 | 0.32 | 1.94 | 0.60 | |
| ≥29 | 0.30 | 0.14 | 0.65 | <0.01 | |
| Chemotherapy | Adjuvant | Reference | |||
| Neo-adjuvant | 0.74 | 0.38 | 1.45 | 0.38 | |
| No chemotherapy | 1.45 | 0.31 | 6.72 | 0.64 | |
| Hormone therapy | Yes | Reference | |||
| No | 1.25 | 0.64 | 2.44 | 0.51 | |
| Fatigue (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 0.74 | 0.41 | 1.33 | 0.31 | |
| Dermatitis radiation (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 1.15 | 0.24 | 5.48 | 0.86 | |
| Dysphagia (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 0.55 | 0.27 | 1.13 | 0.10 | |
| Esophagitis (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 2.10 | 0.81 | 5.46 | 0.13 | |
| Cough (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 0.98 | 0.32 | 3.06 | 0.97 | |
| Dyspnea (grade CTCAE v4.0) | 0 | Reference | |||
| >0 | 1.13 | 0.23 | 5.58 | 0.88 | |
| Any acute radiation reaction (grade CTCAE v4.0) | 0, 1 | Reference | |||
| 2, 3 | 1.69 | 0.87 | 3.28 | 0.12 | |
CI confidence interval, IMRT intensity-modulated radiotherapy, 3DCRT three-dimensional conformal radiotherapy, CF conventional fractionation, HF hypofractionation, CTCAE Common Terminology Criteria for Adverse Events